September 25, 2020

Emerging Opportunities in Multiple Sclerosis and Neurosciences

Date and time

September 24, 2020 ~ September 24, 2020

10:30am – 12:30pm EDT | 4:30pm – 6:30pm CET

Can we build a roadmap to conquer Multiple Sclerosis (MS), a disease that impacts more than 2 million globally as the leading non-traumatic disability disorder in young adults? How have lessons learnt so far shed light on broader neuroscience R&D?

On September 24, join us for “Emerging Opportunities in Multiple Sclerosis and Neurosciences,” the fourth episode in our “Collaborations That Transform” webinar series.

We would like to thank BioCentury, Children’s Tumor Foundation, CLSA, Informa, New England Hemophilia Association and UK Bioindustry Association for their great support of the “Collaborations That Transform” webinar series.

As an industry enabler, WuXi AppTec is committed to improving the lives of patients globally. We share the conviction that we must work collaboratively to solve industry-wide challenges and bring transformative medicines to patients.

We welcome you to the conversation.

Agenda

10:30 AM - 10:30 AM Welcome
Hui Cai, VP and Head of Content, WuXi AppTec, Program Chair
10:30 AM - 10:50 AM Session I: Meeting the Challenges in MS and Neuroscience Drug Development
A conversation with Dietmar Berger, Head of Development and CMO, Sanofi; moderated by Kevin Da Silva, Chief Editor, Nature Neuroscience
10:50 AM - 11:35 AM Session II: Clinical Prospects for a Challenging Disease
Tanuja Chitnis, Professor of Neurology, Harvard Medical School; Director, Partners Pediatric Multiple Sclerosis Center, Massachusetts General Hospital
Mark Freedman, Professor of Neurology, University of Ottawa; Sr. Scientist, The Ottawa Hospital Research Institute
Ari Green, Chief, Division of Neuroinflammation and Glial Biology, Medical Director, Multiple Sclerosis and Neuroinflammation Center, UCSF
Cyndi Zagieboylo, President and CEO, National MS Society
Moderated by Mandy Jackson, Managing Editor of US Commercial News for Scrip and The Pink Sheet
11:35 AM - 12:30 PM Session III: New Directions in MS Therapies
Joachim Herz, Professor, Molecular Genetics, Neuroscience, Neurology; Director, Center for Translational Neurodegeneration Research, UT Southwestern Medical Center
Ralph Kern, President and Chief Medical Officer, Brainstorm Cell Therapeutics
Dan Lorrain, Chief Scientific Officer, Pipeline Therapeutics
Krish Ramanathan, Global Program Head, Neuroscience and Global Drug Development, Novartis
Moderated by Richard Soll, Head of WuXi AppTec’s Boston office; Senior Advisor of Strategic Initiatives

Speakers

Hui Cai
VP AND HEAD OF CONTENT DIVISION, WUXI APPTEC
Kevin Da Silva
CHIEF EDITOR, NATURE NEUROSCIENCE
Dietmar Berger
HEAD OF DEVELOPMENT AND CMO, SANOFI
Ralph Kern
PRESIDENT AND CHIEF MEDICAL OFFICER, BRAINSTORM CELL THERAPEUTICS
Joachim Herz
PROFESSOR, MOLECULAR GENETICS, NEUROSCIENCE, NEUROLOGY; DIRECTOR, CENTER FOR TRANSLATIONAL NEURODEGENERATION RESEARCH, UT SOUTHWESTERN MEDICAL CENTER
Ari Green
CHIEF, DIVISION OF NEUROINFLAMMATION AND GLIAL BIOLOGY, MEDICAL DIRECTOR, MULTIPLE SCLEROSIS AND NEUROINFLAMMATION CENTER, UCSF
Mark Freedman
PROFESSOR OF NEUROLOGY, UNIVERSITY OF OTTAWA; SR. SCIENTIST, THE OTTAWA HOSPITAL RESEARCH INSTITUTE
Tanuja Chitnis
PROFESSOR OF NEUROLOGY, HARVARD MEDICAL SCHOOL
Cyndi Zagieboylo
PRESIDENT AND CEO, NATIONAL MS SOCIETY
Mandy Jackson
MANAGING EDITOR OF US COMMERCIAL NEWS FOR SCRIP AND THE PINK SHEET
Krish Ramanathan
GLOBAL PROGRAM HEAD, NEUROSCIENCE AND GLOBAL DRUG DEVELOPMENT, NOVARTIS
Dan Lorrain
CHIEF SCIENTIFIC OFFICER, PIPELINE THERAPEUTICS
Richard Soll
HEAD OF WUXI APPTEC’S BOSTON OFFICE; SENIOR ADVISOR OF STRATEGIC INITIATIVES